Synageva BioPharma Corp (NASDAQ:GEVA)

214.53
BATS BZX Real-Time Price
As of 9:56am ET
 +0.53 / +0.25%
Today’s Change
60.19
Today|||52-Week Range
218.80
+131.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$8.1B

Company Description

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded on November 2, 2011 and is headquartered in Lexington, MA.

Contact Information

Synageva BioPharma Corp.
33 Hayden Avenue
Lexington Massachusetts 02421
P:(781) 357-9900
Investor Relations:
(781) 357-9947

Employees

Shareholders

Mutual fund holders64.01%
Other institutional45.50%
Individual stakeholders39.93%

Top Executives

Sanj K. PatelPresident, Chief Executive Officer & Director
Robert B. BazemoreChief Operating Officer
Carsten BoessChief Financial Officer & Senior Vice President
Anthony G. QuinnChief Medical Officer & Executive Vice President
Glen WilliamsSenior VP-Global Technical Operations & Quality

To view my watchlist

Not a member yet?

Sign up now for a free account